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A b s t r a c t
Background: In patients with acute ST segment elevation myocardial infarction (STEMI), primary percutaneous coronary inter-
vention (PCI) is the preferred reperfusion method over fibrinolysis, if it is performed in a timely fashion by an experienced team 
in a centre with on-site primary PCI service. Treatment delay due to patient transfer to the cardiac catheterisation laboratory 
is an important limitation of mechanical reperfusion in STEMI patients.
Aim: To analyse treatment outcomes in STEMI patients hospitalised in a regional hospital in Tarnow before and after introduc-
tion of a 24/7 primary PCI service.
Methods: Enrolment into the registry continued for 12 months before introduction of a 24/7 primary PCI service (Period I: 
19.04.2004–19.04.2005) and 15 months after introduction of a 24/7 primary PCI service (Period II: 8.08.2005–19.10.2006). 
Overall, 226 STEMI patients were analysed, including 115 patients in Period I and 111 patients in Period II. STEMI patients in 
Period I received conservative treatment (n = 59), pharmacoinvasive treatment (a half dose of alteplase, a full dose of abciximab, 
and transfer to a 24/7 primary PCI reference centre: n = 32) or fibrinolysis with streptokinase (n = 24), while all patients in 
Period II underwent primary PCI on the first day of hospitalisation. Occurrence of cardiovascular deaths, non-fatal recurrent infarc-
tions, and revascularisation with PCI or coronary artery bypass grafting was evaluated in the two groups during 1-year follow-up.
Results: Reperfusion therapy was used in 48.7% of STEMI patients in Period I (pharmacoinvasive treatment in 27.8% and 
fibrinolysis in 20.9%), and all patients in Period II underwent primary PCI. In-hospital mortality among STEMI patients in 
Period I was significantly higher than in Period II (23.5% vs. 5.4%, p < 0.001), and it was 23.7% in patients managed conser-
vatively. The hazard ratio for Period II compared to Period I was 0.14 (95% CI 0.03–0.62, p = 0.009). A benefit of invasive 
treatment was seen during 1 year of follow-up (mortality 26.1% in Period I vs. 9.0% in Period II, p = 0.001). Invasive treatment 
was also associated with a shorter hospital stay. 
Conclusions: Introduction of a 24/7 primary PCI regional service (STEMI network) led to improved accessibility of invasive 
diagnosis and treatment and increased reperfusion treatment rates, resulting in reduced in-hospital and 1-year mortality 
among STEMI patients. 
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INTRODUCTION
Primary percutaneous coronary intervention (PCI) is the pre-
ferred approach to reperfusion therapy over fibrinolysis if it 
can be performed in a timely fashion by an experienced team 
in a cardiac catheterisation facility providing a 24/7 PCI ser-
vice [1]. Thus, delay related to transferring ST segment eleva-
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tion myocardial infarction (STEMI) patients to a PCI-capable 
hospital may be a limitation of this treatment approach. To 
limit delays to primary PCI, hospital networks are created that 
comprise a core facility providing a 24/7 PCI service, a number 
of cooperating non-PCI-capable hospitals, and emergency 
medical services. This shortens the time to reperfusion (i.e., 
primary PCI) and reduces mortality among STEMI patients. Eu-
ropean and American guidelines recommend developing such 
networks as the basic system of healthcare organisation in the 
management of STEMI [1, 2].
On August 8, 2005, a 24/7 primary PCI service was initi-
ated in a regional hospital in Tarnow, providing PCI services 
for the city of Tarnow and a regional network of cooperating 
non-PCI-capable hospitals.
The aim of this study was to evaluate outcomes in STEMI 
patients hospitalised in the regional hospital in Tarnow before 
and after initiation of a 24/7 primary PCI service.
METHODS
The study group included consecutive STEMI patients present-
ing to the E. Szczeklik Specialist Hospital in Tarnow, Poland.
The diagnosis of STEMI was based on generally accepted 
criteria (typical chest pain, new ST segment elevation or new 
left bundle branch block in the electrocardiogram [ECG]).
The study was a prospective registry, with data collec-
tion from two periods, from April 19, 2004 to April 19, 2005 
(Period I, before initiation of a 24/7 primary PCI service), and 
from August 8, 2005 to October 19, 2006 (Period II, after 
initiation of a 24/7 primary PCI service).
During Period I, patients with the initial diagnosis of an 
acute coronary syndrome were admitted to the cardiology 
unit in Tarnow or, in case of STEMI presentation within 12 h, 
they were transferred directly from the emergency room to 
the Department of Haemodynamics and Angiocardiography 
at the Institute of Cardiology, Jagiellonian University Medical 
College in Krakow, following a telephone consultation with 
a cardiologist on duty who made a decision to proceed with 
invasive coronary angiography. Due to expected significant 
transfer-related delay, a pharmacoinvasive strategy was 
employed in these patients, including initial drug therapy 
(aspirin, a reduced dose of unfractionated heparin, full dose 
of a glycoprotein IIb/IIIa inhibitor abciximab, and a half dose 
of alteplase) before transfer for PCI. STEMI patients who 
stayed in the local hospital in Tarnow received fibrinolytic 
therapy (streptokinase at a standard dose of 1.5 million units 
intravenously over 60 min) if not contraindicated, or received 
medical therapy (i.e., no reperfusion therapy) and were re-
ferred for invasive coronary angiography at the local cardiac 
catheterisation laboratory during the index hospitalisation.
During Period II, STEMI patients underwent immediate 
coronary angiography and primary PCI.
Data were collected during hospitalisation using medi-
cal charts and records according to the established standards 
and entered to the registry database. One-year follow-up 
data were collected by a telephone interview with patients 
or their families. In this way, complete 1-year follow-up data 
were obtained for both study groups.
We analysed in-hospital data (treatment outcomes 
including the following endpoints: cardiovascular death, 
recurrent non-fatal infarction, and PCI or coronary artery 
bypass grafting [CABG] due to recurrent ischaemia within the 
territory of the vessel treated with PCI) and 1-year follow-up 
data. A combined endpoint was defined as the sum of all 
individual endpoints.
The study was approved by a Bioethics Committee at the 
Regional Medical Chamber in Tarnow.
Statistical analysis
Continuous variables were described with arithmetic means 
and standard deviation. The Student t test or non-parametric 
Mann-Whitney test was used to compare mean values of 
continuous variables in the two study groups. Categorical 
variables were reported as numbers and percentages, and 
their distributions in the two study groups were compared 
using the c2 test or exact Fisher test. Survival was estimated 
using the Kaplan-Meier method, and log rank test was used 
to compare the two study groups. Hazard ratio (HR) was esti-
mated using a Cox regression model. P < 0.05 was considered 
statistically significant. All calculations were performed using 
the STATISTICA 8 software (StatSoft, Poland).
RESULTS
The registry included 226 STEMI patients who were divided 
into two groups depending on whether data were collected 
before (Group I, n = 115) or after (Group II, n = 111) initia-
tion of a 24/7 primary PCI service.
Comparison of patient groups
Patients in Group I had more advanced peripheral atheroscle-
rosis (intermittent claudication, a history of stroke). Patients in 
Group I presented later (with longer time from the onset of chest 
pain to hospitalisation) and had lower blood pressure on admis-
sion, with no differences in the Killip classification (Table 1). We 
found no differences regarding in-hospital drug therapy, except 
for more frequent use of clopidogrel in Group II. In Group II, 
duration of hospital stay was shorter and PCI rate was higher 
compared to the period before initiation of a 24/7 PCI service. 
In Period II, in-hospital and 1-year cardiovascular mortality 
was significantly reduced compared to Period I. We found no 
differences in the rates of recurrent non-fatal infarction and 
repeated PCI/CABG (Table 2, Figs. 1, 2).
Treatment outcomes in Group I
During Period I, only 27.8% of STEMI patients underwent 
mechanical reperfusion on the first day of hospital stay, 20.9% 
of patients were treated with fibrinolysis, and the remaining 
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patients were managed conservatively. In Group I, coronary 
angiography was performed during the index hospitalisation in 
only 59.1% of patients, as the remaining patients did not con-
sent to invasive coronary angiography. The lowest in-hospital 
cardiovascular mortality was found among patients receiving 
pharmacoinvasive treatment.
Comparison of Group I patients treated  
with fibrinolysis and patients not receiving  
reperfusion therapy and Group II patients 
During Period II, all STEMI patients were treated with me-
chanical reperfusion. Duration of hospital stay was shorter, and 
patient survival was significantly higher compared to patients 
Table 1. Study group characteristics
STEMI I STEMI II P 
Number of patients n = 115 n = 111
Age, mean ± SD [years] 63.5 ± 12.7 63.6 ± 11.2 0.94
Men [%] 73.9 68.5 0.37
Past medical history:
Hypercholesterolaemia [%] 21.7 32.4 0.07
Hypertension [%] 67.8 64.9 0.64
Smoking [%] 46.1 41.4 0.48
Previous MI [%] 13.9 14.4 0.91
Previous PCI [%] 3.5 2.7 0.74
Previous CABG [%] 0.0 0.0 –
Symptoms of heart failure [%] 5.2 0.9 0.06
Previous stroke [%] 9.6 2.7 0.032*
Peripheral arterial disease [%] 11.3 3.6 0.028*
Diabetes [%] 16.5 19.8 0.31
Renal failure [%] 0.0 0.0 –
Hospitalisation:
Heart rate on admission [bpm] 82.8 ± 19.5 83.3 ± 17.8 0.84
Systolic BP on admission [mm Hg] 134.8 ± 24.9 145.8 ± 30.5 0.004*
Diastolic BP on admission [mm Hg] 84.9 ± 15.8 89.7 ± 18.1 0.042*
Killip class on admission [%]:
1 + 2
3 + 4
87.0
13.0
89.0
11.0 0.64
Time from the onset of pain to admission [h]:
0–3
3–6
6–12
12–24
> 24
33.0
21.4
12.6
14.6
18.4
29.3
39.4
26.3
4.0
1.0
< 0.001*
Anterior wall infarction [%] 30.9 42.3 0.12
LVEF during hospitalisation [%] 50.1 ± 11.6 49.4 ± 12.9 0.72
GFR (mL/min/1.73 m2): < 60 13.5 14.7 0.60
Duration of hospital stay [days] 11.1 ± 4.6 6.0 ± 2.7 < 0.001*
Fibrinolytic therapy [%] 20.9 0.0 <0.001*
Coronary angiography during hospitalisation [%] 59.1 100.0 < 0.001*
Single-vessel disease [%] 48.5 36.9 0.13
PCI during hospitalisation [%] 50.4 100.0 < 0.001*
*Statistical significance; BP — blood pressure; CABG — coronary artery bypass grafting; GFR — glomerular filtration rate; LVEF — left ventricu-
lar ejection fraction; MI — myocardial infarction; PCI — percutaneous coronary intervention; SD — standard deviation; STEMI — ST elevation 
myocardial infarction
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treated with fibrinolysis and patients not receiving reperfusion 
therapy during Period I (Tables 3, 4).
A multivariate Cox regression model was developed 
to determine HR adjusted for a history of ischaemic heart 
disease, previous stroke, peripheral arterial disease, time 
from the onset of symptoms to hospitalisation, and systolic 
blood pressure on admission. HR for Period II compared to 
Period I was 0.14 (95% CI 0.03–0.62, p = 0.009), and thus 
the risk of dying during the first 30 days after the procedure 
was significantly lower in Period II compared to Period I. 
Unadjusted HR was 0.08 (95% CI 0.02–0.35, p = 0.001). 
DISCUSSION
Our findings indicate a significant effect of introducing 
a regional primary PCI service network on the reduction of 
mortality in STEMI patients.
The European Society of Cardiology guidelines on the 
management of STEMI recommend primary PCI as the pre-
ferred reperfusion therapy if it can be performed in a timely 
fashion by an experienced team [1]. However, as indicated 
by the registry data, keeping the recommended maximum 
PCI delay may be difficult in practice, particularly when 
STEMI patients present to non-PCI-capable hospitals [3, 4]. 
In addition, despite established benefits from primary PCI, 
this approach is still not commonly used and a large number 
of STEMI patients receive no reperfusion therapy at all [5, 6]. 
Delaying mechanical reperfusion leads to worse treatment 
outcomes. In the analysis by De Luca et al. [7], each 30-min 
delay was associated with a 7.5% relative increase in 1-year 
mortality. Similarly, an increase in 6-month mortality in rela-
tion to a delay of reperfusion therapy was found in an analysis 
of the GRACE registry findings [8]. Of importance, available 
data indicate that the need for patient transfer to a hospital 
providing 24/7 PCI capability may result in such a delay of 
reperfusion therapy that its benefit over immediate fibrinolysis 
is largely reduced or even abolished. In the analysis by Pinto et 
al. [9], mortality difference between patients treated with pri-
mary PCI or fibrinolysis was eliminated when the delay of PCI 
(in relation to fibrinolysis) was more than 114 min. This time 
was different in different patients subgroups and was related to 
Table 2. Treatment outcomes
STEMI I STEMI II P
Number of patients n = 115 n = 111
CV death during hospitalisation [%] 23.5 5.4 < 0.001*
CV death at 1 year [%] 26.1 9.0 0.001*
Recurrent infarction at 1 year [%] 4.4 3.6 0.77
PCI at 1 year [%] 2.6 3.6 0.67
CABG at 1 year [%] 0.9 5.4 0.049*
Death + recurrent infarction + PCI/CABG at 1 year [%] 29.6 12.6 0.002*
*Statistical significance; CABG — coronary artery bypass grafting; CV — cardiovascular; PCI — percutaneous coronary intervention; STEMI —  
ST elevation myocardial infarction
Figure 1. Kaplan-Meier curves for overall survival in  
ST elevation myocardial infarction (STEMI) patient groups 
(Period I vs. Period II)
Figure 2. Kaplan-Meier curves for survival free from the com-
bined endpoint in ST elevation myocardial infarction (STEMI) 
patient groups (Period I vs. Period II)
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the onset of clinical symptoms, patient age, and infarct locali-
sation. In the analysis by De Luca et al. [10], the difference in 
mortality was abolished when PCI was delayed by more than 
180 min, while in the metaanalysis by Boersma et al. [11], 
PCI had an advantage over fibrinolysis despite a treatment 
delay of 120 min (larger delays were not observed). To reduce 
PCI delays due to logistic problems, a concept of regional 
STEMI treatment network was developed, comprising a core 
facility with 24/7 PCI capability, a number of cooperating 
non-PCI-capable hospitals, and emergency medical services 
Table 3. Hospital treatment data and outcomes in subgroups. STEMI I group (fibrinolytic therapy vs. medical therapy, pharmaco-
invasive therapy vs. medical therapy). Medical therapy defined as no coronary intervention during the first day of hospitalisation
Fibrinolytic 
therapy
Medical 
therapy
P Pharmaco­
invasive 
therapy
Medical 
therapy
P
Number of patients n = 24 n = 59 n = 32 n = 59
Duration of hospital stay [days] 10.2 ± 8.0 9.7 ± 5.6 0.78 9.8 ± 5.5 9.7 ± 5.6 0.94
Fibrinolytic therapy [%] 37.5 23.7 0.20 9.4 23.7 0.09
Coronary angiography during hospitalisation [%] 20.8 52.5 0.008* 100.0 52.5 < 0.001*
Single-vessel disease [%] 20.8 25.4 0.66 40.6 25.4 < 0.001*
PCI during hospitalisation [%] 16.7 37.3 0.07 100.0 37.3 < 0.001*
CV death during hospitalisation [%] 37.5 23.7 0.20 9.4 23.7 0.09
CV death at 1 year [%] 37.5 30.5 0.54 9.4 30.5 0.022*
Recurrent infarction at 1 year [%] 4.2 3.4 0.86 6.3 3.4 0.52
PCI at 1 year [%] 4.2 0.0 0.11 6.3 0.0 0.05
CABG at 1 year [%] 0.0 1.7 0.52 0.0 1.7 0.46
Death + recurrent infarction + PCI/CABG at 1 year [%] 41.7 32.2 0.41 15.6 32.2 0.09
*Statistical significance; CABG — coronary artery bypass grafting; CV — cardiovascular; PCI — percutaneous coronary intervention; STEMI —  
ST elevation myocardial infarction
Table 4. Hospital treatment data and outcomes in subgroups (continued). STEMI I and STEMI II groups (fibrinolytic therapy in  
Period I vs. primary PCI in Period II, medical therapy in Period I vs. primary PCI in Period II). Medical therapy defined as no corona-
ry intervention during the first day of hospitalisation
STEMI I  
Fibrinolytic 
therapy
STEMI II
Primary PCI
P STEMI I
Medical 
therapy
STEMI II
Primary PCI
P
Number of patients n = 24 n = 111 n = 59 n = 111
Duration of hospital stay [days] 10.2 ± 8.0 6.0 ± 2.7 < 0.001* 9.7 ± 5.6 6.0 ± 2.7 < 0.001*
Fibrinolytic therapy [%] 37.5 0.0 < 0.001* 23.7 0.0 < 0.001*
Coronary angiography during  
hospitalisation [%]
20.8 100.0 < 0.001* 52.5 100.0 < 0.001*
Single-vessel disease [%] 20.8 36.9 < 0.001* 25.4 36.9 < 0.001*
PCI during hospitalisation [%] 16.7 100.0 < 0.001* 37.3 100.0 < 0.001*
CV death during hospitalisation [%] 37.5 5.4 < 0.001* 23.7 5.4 < 0.001*
CV death at 1 year [%] 37.5 9.0 < 0.001* 30.5 9.0 < 0.001*
Recurrent infarction at 1 year [%] 4.2 3.6 0.90 3.4 3.6 0.94
PCI at 1 year [%] 4.2 3.6 0.90 0.0 3.6 0.14
CABG at 1 year [%] 0.0 5.4 0.24 1.7 5.4 0.25
Death + recurrent infarction  
+ PCI/CABG at 1 year [%]
41.7 12.6 0.001* 32.2 12.6 0.002*
*Statistical significance; CABG — coronary artery bypass grafting; CV — cardiovascular; PCI — percutaneous coronary intervention; STEMI —  
ST elevation myocardial infarction
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system [1, 2, 12, 13]. As indicated by our findings, such or-
ganisation of care increases accessibility of reperfusion therapy 
(by increasing the rate of primary PCI) among STEMI patients 
and reduces mortality in this patient population. Similarly to 
our study, Saia et al. [14] showed that introduction of regional 
primary PCI network was associated with an increased rate of 
reperfusion therapy among STEMI patients by increasing the 
proportion of patients treated with primary PCI, while the rate 
of fibrinolytic therapy was reduced. Introduction of this treat-
ment network was also associated with a mortality reduction. 
Similar associations were noted in an analysis of the Vienna 
STEMI Registry [15]. In our registry, the highest cardiovascular 
mortality in Period I was observed among patients who did 
not receive pharmacoinvasive therapy (treated with on-site 
fibrinolysis or not receiving reperfusion therapy). This may be 
largely related to a high risk profile of these patients, but also 
unavailability of primary PCI which might be the treatment 
of choice in many of these patients despite their concomitant 
conditions. If transfer within the recommended time limits 
is not possible, an intermediate solution may be so-called 
pharmacoinvasive strategy that encompasses initial lytic treat-
ment followed by immediate patient transfer to a hospital with 
24/7 PCI capability with a view to coronary angiography and 
possibly PCI. This treatment model was employed in the first 
period of our registry [16, 17]. Benefits of such management 
strategy compared to fibrinolysis without immediate patient 
transfer to a hospital with 24/7 PCI capability (transfer only 
for rescue or elective PCI) were shown in the CARESS in AMI 
and TRANSFER AMI studies [18, 19]. Of note, however, such 
an approach also has some limitations, for example related 
to contraindications to fibrinolysis and in practice it is most 
commonly employed in patients with low bleeding risk.
Limitations of the study
The major limitation of our study was a low number of pa-
tients. The study was a non-randomised registry. However, 
performing a randomised study to evaluate the effect of STEMI 
care organisation does not seem feasible [20]. A registry that 
includes consecutive hospitalised patients allows evaluation 
of treatment outcomes during everyday clinical practice. In 
our registry, we did not evaluate delays from the first medical 
contact to administration of various reperfusion therapies dur-
ing the study periods. Although these data are several years’ 
old, our findings remain important and highlight benefits of 
reducing PCI delays by development of hospital networks 
that include a core PCI facility, a number of cooperating 
non-PCI-capable hospitals, and appropriately prepared emer-
gency medical services [1, 2, 6, 21, 22].
CONCLUSIONS
Introduction of a 24/7 primary PCI regional service (STEMI 
network) led to increased reperfusion treatment rates and 
improved accessibility of invasive diagnosis and treatment, 
resulting in reduced in-hospital and 1-year mortality among 
STEMI patients. 
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S t r e s z c z e n i e
Wstęp: Zabiegi pierwotnej przezskórnej interwencji wieńcowej (PCI) stanowią preferowaną metodę leczenia reperfuzyjnego 
pacjentów z zawałem serca z uniesieniem odcinka ST (STEMI) w stosunku do fibrynolizy, jeśli mogą być wykonane w odpo-
wiednim przedziale czasowym, przez doświadczony personel, w ośrodku prowadzącym całodobowy dyżur hemodynamiczny. 
Opóźnienie związane z logistyką przekazania chorego z STEMI do pracowni hemodynamiki może być ograniczeniem dla 
tej metody terapii.
Cel: Celem pracy była ocena wyników leczenia pacjentów z STEMI hospitalizowanych w Szpitalu Powiatowym w Tarnowie 
w okresie przed i po wprowadzeniu dyżuru hemodynamicznego.
Metody: Rejestr obejmował 12-miesięczny Okres I (19.04.2004–19.04.2005) przed wprowadzeniem dyżuru hemodynamicz-
nego i 15-miesięczny Okres II (8.08.2005–19.10.2006) po wprowadzeniu całodobowego dyżuru hemodynamicznego. Do 
badania włączono 226 pacjentów z STEMI (Okres STEMI I: n = 115, Okres STEMI II: n = 111). Pacjenci z grupy STEMI I byli 
leczeni zachowawczo (n = 59), farmakoinwazyjnie (farmakoterapia za pomocą połowy dawki lityku — alteplazy z pełną 
dawką abciximabu, a następnie transfer do ośrodka referencyjnego w celu wykonania koronarografii/PCI) (n = 32), a u części 
chorych zastosowano terapię lityczną streptokinazą (n = 24), natomiast w Okresie II u wszystkich pacjentów wykonano za-
bieg pierwotnej PCI w 1. dobie hospitalizacji. Grupy zostały poddane rocznej obserwacji, w czasie której oceniano częstość 
występowania zgonów z przyczyn sercowo-naczyniowych, ponownych zawałów serca niezakończonych zgonem i zabiegów 
rewaskularyzacyjnych PCI/pomostowania aortalno-wieńcowego.
Wyniki: Terapię reperfuzyjną zastosowano u 48,7% pacjentów z grupy STEMI I (leczenie farmakoinwazyjne: 27,8%, terapia 
lityczna: 20,9%) oraz u wszystkich pacjentów z grupy STEMI II (pierwotna PCI 100%). Śmiertelność wewnątrzszpitalna w grupie 
STEMI I była istotnie wyższa niż w grupie STEMI II (23,5% vs. 5,4%; p < 0,001), a w grupie chorych leczonych zachowawczo 
wynosiła 23,7%. Iloraz ryzyka (HR) dla Okresu II w porównaniu z Okresem I wyniósł 0,14 (95% CI 0,03–0,62; p = 0,009). 
Korzyść z zastosowania leczenia inwazyjnego utrzymywała się w obserwacji 12-miesięcznej (śmiertelność STEMI I vs. STEMI II: 
26,1% vs. 9,0%; p = 0,001). Zastosowanie leczenia inwazyjnego skracało czas hospitalizacji pacjentów z STEMI. 
Wnioski: Wprowadzenie regionalnego programu pierwotnej PCI opartego na sieci terapii interwencyjnej zawału pozwoliło na 
zwiększenie częstości leczenia reperfuzyjnego oraz zwiększenie dostępności do diagnostyki i terapii inwazyjnej. Po wprowadzeniu 
regionalnego programu pierwotnej PCI stwierdzono mniejszą śmiertelność wewnątrzszpitalną i roczną u pacjentów z STEMI. 
Słowa kluczowe: zawał serca, rejestr, pierwotna przezskórna interwencja wieńcowa, zgon sercowo-naczyniowy, sieć terapii 
interwencyjnej zawału 
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